CLINICAL AND VIROLOGICAL EVALUATION OF THE DRUG

L. V. Pogorelskaya; I. N Khlopova; S. S Grigoryan; I. P Tryakina; N. A Rik; D. G Mal'dov

doi:10.17816/EID40702

Epidemiology and Infectious Diseases ›› 2013, Vol. 18 ›› Issue (3) : 14 -18. DOI: 10.17816/EID40702

Articles

research-article

CLINICAL AND VIROLOGICAL EVALUATION OF THE DRUG "STIMFORTE" IN ACUTE HEPATITIS B

Author information +

History +

PDF

Abstract

Gamalei Str., Moscow, Russia, 123098; 4Closed 4Joint-Stock Company “SKY LTD”, 113/1, Leninsky avenue, Moscow, Russian Federation, 117108 Hepatitis B is a serious problem for global health. The incidence of acute hepatitis B in the Russian Federation in recent years was 2.2 per 100 000 people. In 5% of cases the infection can acquire chronic course, leading to the development of cirrhosis and hepatocellular carcinoma. Recently, there is increased interest in drugs of plant and animal origin which have immunomodulatory and antiviral activity. "Stimforte" is one out of such drugs. The aim of this work was to determine the as clinical and immunologic as virologic efficacy of the injectable form of the drug. The study included 30 patients and 22 subjects from the control group. Evaluation of treatment efficacy was performed on the results of clinical and laboratory examination and was determined in the terms of reverse development of acute viral hepatitis, dynamics and rate of downword in activity of biochemical parameters (ALT, AST, alkaline phosphatase), elimination of markers of acute hepatitis from the blood, the frequency of formation of chronic hepatitis. The investigation of immune and interferon status was performed. At the same time the possible occurrences of adverse reactions were taken into account. At the end of the study the use of "Stimforte " was shown to have a positive effect on the regression of clinical symptoms of the disease, by reducing their duration by 2-8 days, contributed to a more rapid normalization of indices of cytolysis (ALT, AST). Drug "Stimforte" has immunomodulatory effect, stimulated antiviral immune response to acute HBV-infection. Within 6 months of following up patients no chronic cases were observed. The drug was well tolerated by all patients with no incidence of adverse reactions.

Keywords

Acute hepatitis B / an immune modulator / "Stimforte" / treatment

Cite this article

Download citation ▾

L. V. Pogorelskaya, I. N Khlopova, S. S Grigoryan, I. P Tryakina, N. A Rik, D. G Mal'dov. CLINICAL AND VIROLOGICAL EVALUATION OF THE DRUG "STIMFORTE" IN ACUTE HEPATITIS B. Epidemiology and Infectious Diseases, 2013, 18(3): 14-18 DOI:10.17816/EID40702

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	W. Ray Kim, Epidemiology of Hepatitis B in the United States. Hepatology. 2009 May; 49(5 Suppl): S28-34.

[2]	Дерябин П.Г., Е.И. Исаева, Д.Г. Мальдов, А.В. Ильичев, Л.В.Пичугина, Львов Д.К. - Действие Стимфорте на устойчивый к интерферону генотип штамма вируса гепатита С. Вопр. Вирусологии 2009; 2: 17 - 20.

[3]	Зыкова И.Н., Шульженко А. Е., Пинегин Б.В., Мальдов Д.Г., Ильичев А.В. - Применение препарата «Стимфорте» в комплексной терапии рецидивирующей герпесвирусной инфекции. Герпес. 2009; 2: 30-36.

[4]	Ильичев А.В., Бельков А.П., Мальдов Д.Г., Асташкин Е.И.-Секреция гранул нейтрофилов человека под действием формил пептида и препарата «Стимфорте». Иммунология, 2009; 3: 159-61.

[5]	Мальдов Д.Г., Галегов Г.А., Андронова В.Л., Ильичев А.В., Бельков А.П. - Действие «Стимфорте» на основные характеристики воспаления при заражении экспериментальных животных впг I. Антибиотики и химиотерапия 2011.

[6]	Российский статистический ежегодник. Заболеваемость населения по основным классам болезней.М: Федеральная служба государственной статистики. 2011.